Clinical Trial Update: Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating a base-edited hematopoietic stem/progenitor cell gene therapy for X-linked severe combined immunodeficiency (X-SCID). T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Severe Combined Immunodeficiency

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: X-linked Severe Combined Immunodeficiency, X-SCID | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION